Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Rather than pursuing unproven combinations of investigational and licensed agents, patients are encouraged to: Engage with NHS weight management services , which offer multidisciplinary support including dietary advice, behavioural therapy, and pharmacotherapy where appropriate including orlistat and, where eligible, GLP-1-based medicines Discuss licensed options with their GP if they meet eligibility criteria, including referral pathways for bariatric surgery in line with NICE obesity guidance Participate in clinical trials if interested in investigational agents such as retatrutide, through legitimate research pathways listed on the NIHR Clinical Research Network or ClinicalTrials.gov The safest and most effective treatments are those supported by robust clinical evidence, prescribed by qualified clinicians, and obtained through regulated supply chains
Muscle mass loss during GLP-1 receptor agonist therapy prevented with GDF8 and activin A blockade
Green synthesis of copper nanoparticles using Cissus vitiginea and its antioxidant and antibacterial activity against urinary tract infection pathogens
In some cases gastrointestinal discomfort or a fishy body odour may appear, associated with metabolites such as trimethylamine
For use as approved by the Independent Review Board (IRB) according to the IRB Charter (see www.novonordisk-trials.com)
